More Stelara Rivals Hit US, With Discounts Already Reaching 85%
Teva, Sandoz And Biocon Confirm Ustekinumab Biosimilar Launches
As more Stelara biosimilars pile into the US market – including launches from Alvotech/Teva, Samsung Bioepis/Sandoz and Biocon – the latest data suggests that price competition for ustekinumab rivals could be fierce, with Teva and Sandoz both confirming to Generics Bulletin details of significant discounts to the brand.
